Highest-materiality recent filing
NeoGenomics issues $316.25M of 0.75% convertible notes due 2032, repurchases $276M of existing notes
Issued $316.25M aggregate principal of 0.75% Convertible Senior Notes due 2032, conversion price ~$14.16 (35% premium to $10.49 close).
NeoGenomics prices $275M convertible notes due 2032; to repurchase $276M of existing notes
$275M principal of 0.75% convertible notes due 2032; initial purchasers have option for additional $41.25M.
NeoGenomics commences $275M convertible note offering due 2032
Offering $275M aggregate principal amount of convertible senior notes due 2032, with option for additional $41.25M.
NeoGenomics Q1 revenue up 11% to $187M; raises FY2026 guidance to $797-803M
Consolidated revenue $187M (+11% YoY); Clinical revenue +14%, NGS +26%.
Q4 consolidated revenue $190M (+11% YoY); full-year revenue $727M (+10% YoY); clinical revenue grew 15% excluding Pathline.
Preliminary Q4 2025 revenue ~$190M (+11% YoY); full-year 2025 revenue ~$727M (+10% YoY).
NeoGenomics Q3 revenue up 12% to $188M; net loss widens 53% to $27M
Revenue of $188M, +12% YoY; clinical revenue +18% and NGS +24% to ~1/3 of clinical.
NeoGenomics Q2 revenue up 10% to $181M but net loss widens to $45M; cuts full-year guidance
Revenue $181M (+10% YoY); clinical revenue grew 16% (13% ex-Pathline).
NeoGenomics Q1 revenue up 8% to $168M; adjusted EBITDA turns positive at $7M
Consolidated revenue $168M (+8% YoY); net loss improved 4% to $26M.
NeoGenomics Q4 revenue +11% to $172M; FY24 $661M; guides FY25 rev $735-745M
Q4 consolidated revenue $172M (up 11% YoY); net loss $15M vs $14M in Q4 2023.
NeoGenomics guides 2025 revenue $735-745M, adj. EBITDA $55-58M; issues retention bonuses
2025 revenue guidance $735-745M (midpoint $740M) vs FY24 $661M, ~12% YoY growth.
NeoGenomics CEO Chris Smith to retire April 1; board member Tony Zook named successor
Chris Smith retires as CEO effective April 1, 2025; will serve as special advisor through Feb 2027 at $23,913/month.
NeoGenomics Q3 revenue up 10% to $168M; adjusted EBITDA up 305%, raises FY guidance to $37-40M
Consolidated revenue $168M (+10% YoY); Clinical Services revenue $146M (+14%) with test volume +9%.
NeoGenomics Q2 revenue $165M (+12% YoY); raises FY2024 EBITDA guidance to $33-37M
Q2 revenue $165M (+12% YoY); net loss narrowed 23% to $19M.
NeoGenomics Q1 revenue up 14% to $156M; Adjusted EBITDA turns positive at $3M
Clinical Services revenue rose 17% to $135M; test volume up 5% YoY, revenue per test up 11% to $447.
NeoGenomics eliminates President, Advanced Diagnostics role; promotes Harris and Stone
Vishal Sikri steps down as President, Advanced Diagnostics; role eliminated in restructuring.
NeoGenomics Q4 revenue $156M (+12% YoY); FY loss narrows 39% to $88M; guides FY24 rev $650-660M
Q4 consolidated revenue $156M (+12% YoY); Clinical Services +20% to $130M, Advanced Diagnostics -17% to $25M.
NeoGenomics Q3 revenue up 18% to $152M, net loss halved, raises FY guidance
Consolidated revenue $152M (+18% YoY); Clinical Services $128M (+20%), Advanced Diagnostics $24M (+8%).
NeoGenomics Q2 revenue up 18% to $147M; net loss narrows 31% to $24M
Revenue of $147M (+18% YoY); Clinical Services $123M (+17%), Advanced Diagnostics $24M (+22%).
NeoGenomics Q1 revenue up 17% to $137M; narrows net loss; raises FY2023 guidance
Consolidated revenue $137M (+17% YoY); Clinical +16% to $115M, Pharma +22% to $22M.
Q4 revenue $139M (+10% YoY); full year revenue $510M (+5% YoY).
NeoGenomics appoints Jeffrey S. Sherman as CFO; William Bonello steps down
Jeffrey S. Sherman named CFO effective Dec 7, 2022; William Bonello remains as employee for transition support.
NeoGenomics Q3 revenue $129M (+6%); net loss widens to $37M, adjusted EBITDA -$12M
Revenue $129M (+6% YoY); Clinical Services $106M (+4%), Pharma Services $23M (+18%).
NeoGenomics Q2 revenue $125M (+3%), net loss $35M; appoints Chris Smith CEO
Revenue $125M (+3% YoY); Clinical $106M (+4%), Pharma $19M (-4%). Net loss $35M vs $76M income (incl $97M Inivata gain).
NeoGenomics appoints Chris Smith as CEO effective Aug 15, 2022; Tetrault resumes Chair
Chris Smith, former CEO of Ortho Clinical Diagnostics, appointed CEO effective August 15, 2022.
On June 19, 2025, the Board of Directors of NeoGenomics, Inc. (the "Company") increased the size of the Board of Directors (the "Board") from nine to ten members and appointed Marjorie C. Green as a director to fill the vacancy resulting from that increase.
On March 18, 2025, NeoGenomics, Inc. (the "Company") announced the promotion of Warren Stone, the Company's current Chief Commercial Officer, to the position of President & Chief Operating Officer, effective April 1, 2025.
Additionally, on March 18, 2025, the Company announced that the Chief Operations Officer and President, Oncology Data Solutions position is being eliminated and as a result, Melody Harris, the current Chief Operations Officer and President, Oncology Data Solutions will no longer hold such role effective April 1, 2025.
Additionally, on March 18, 2024, the Company announced that the Chief Operations Officer position is being eliminated and as a result, Melody Harris, the current Chief Operations Officer, will no longer hold such role and will no longer be a named executive officer effective April 1, 2025.
On March 18, 2025, NeoGenomics, Inc. (the "Company") announced the promotion of Warren Stone, the Company's current Chief Commercial Officer, to the position of President & Chief Operating Officer, effective April 1, 2025.
The Special Advisor Agreement provides that Mr. Smith will serve as a special advisor to the Company’s Chief Executive Officer until February 26, 2027 in exchange for a fee of $23,913 per month.
Christopher Smith, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), will retire effective April 1, 2025
Christopher Smith, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), will retire effective April 1, 2025
On January 10, 2025, the Company announced the appointment of Tony Zook to replace Mr. Smith as Chief Executive Officer effective April 1, 2025.
On November 1, 2024, the Board of Directors of the Company, appointed Felicia Williams to serve as a member of the Board, the Company’s Audit and Finance Committee (the “Audit Committee”) and the Company’s Nominating and Corporate Governance Committee (the “NCG Committee”).
as a result, Vishal Sikri, the current President, Advanced Diagnostics, will no longer hold such role
Melody Harris, presently the Company's President, Enterprise Operations will now serve as the Company's Chief Operations Officer and President, Informatics.
Max materiality 0.85 · Median 0.57 · Most common event leadership